We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00060515
First Posted: May 8, 2003
Last Update Posted: August 5, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Repligen Corporation
May 7, 2003
May 8, 2003
August 5, 2005
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00060515 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease
An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases
The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Primary Purpose: Treatment
Mitochondrial Diseases
Drug: RG2133 (2',3',5'-tri-O-acetyluridine)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
12
Not Provided
Not Provided
Mitochondrial Disease
Sexes Eligible for Study: All
3 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT00060515
RG2133-01
Not Provided
Not Provided
Not Provided
Not Provided
Repligen Corporation
Not Provided
Not Provided
Repligen Corporation
August 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP